Luspatercept Brand Name– REBLOZYL
What is Luspatercept
Luspatercept is an erythroid maturation agent. It is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions and adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts or with MDS/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis who failed an erythropoiesis stimulating agent and require 2 or more RBC units over an 8-week period.
Thromboembolism has been reported in luspatercept-treated patients; monitor for signs and symptoms of thromboembolism and initiate prophylaxis in at-risk patients.
Indications
- anemia
- myelodysplastic syndrome (MDS)
For the treatment of anemia in patients with beta thalassemia who require regular red blood cell transfusions
NOTE: Luspatercept is not indicated as a substitute for RBC transfusions in patients who require immediate correction of anemia.
Side Effects
- abdominal pain
- antibody formation
- arthralgia
- asthenia
- bone pain
- bone pain
- cough
- diarrhea
- diarrhea
- dizziness
- dizziness
- dyspnea
- dyspnea
- elevated hepatic enzymes
- fatigue
- fatigue
- headache
- headache
- hyperbilirubinemia
- hypertension
- hypertension
- hypertensive crisis
- hyperuricemia
- hyperuricemia
- infection
- infection
- influenza
- injection site reaction
- musculoskeletal pain
- musculoskeletal pain
- nausea
- nausea
- nephrotoxicity
- new primary malignancy
- pulmonary embolism
- sinus tachycardia
- stroke
- syncope
- syncope
- thromboembolism
- thrombosis
- vertigo
- vertigo
Monitoring Parameters
- blood pressure
- hemoglobin/hematocrit
- pregnancy testing
Contraindications
- anemia
- breast-feeding
- children
- contraception requirements
- hypertension
- infants
- infertility
- neonates
- pregnancy
- pregnancy testing
- reproductive risk
- thromboembolism
- thrombosis
- tobacco smoking
Interactions
There are no drug interactions associated with Luspatercept products.
